Anixa Biosciences (ANIX) Gross Margin (2010 - 2023)

Anixa Biosciences' (ANIX) quarterly Gross Margin came in at 23.33% in Q2 2023, down 76.67% on a QoQ basis from 100.0% in Q4 2021.

Anixa Biosciences (ANIX) Gross Margin (2010 - 2023) Analysis & Trends

Anixa Biosciences (ANIX) has 11 years of Gross Margin data on file, last reported at 23.33% in Q2 2023.

Quarterly Gross Margin changed N/A year-over-year to 23.33% in Q2 2023, while the trailing twelve-month figure through Oct 2023 was 22.97% (changed N/A YoY) and the FY2023 annual result came in at 23.33%, changed N/A from the prior year.
Gross Margin retreated to 23.33% in Q2 2023, from 100.0% in the prior quarter.
In the past five years, Gross Margin ranged from a high of 100.0% in Q4 2021 to a low of 23.33% in Q2 2023.
A 3-year average of 45.45% and a median of 29.23% in 2019 frame the typical range for Gross Margin.
The widest YoY moves for Gross Margin: up 26 bps in 2019, down 26 bps in 2019.
Tracing ANIX's Gross Margin over 3 years: stood at 33.5% in 2019, then surged by 199 bps to 100.0% in 2021, then plunged by 77 bps to 23.33% in 2023.
The last three Gross Margin figures came in at 23.33% (Q2 2023), 100.0% (Q4 2021), and 24.95% (Q1 2021), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	91.59%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	90.43%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	35.86%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	76.90%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	63.27%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	84.20%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Anixa Biosciences	123.62 Mn	123.62 Mn	-	-

Download Data